Scribe Therapeutics Completes Initial Public Offering and Private Placement

Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company focused on engineering in vivo CRISPR technologies aimed at extending healthy lifespans through disease prevention and therapeutic interventions, announced the successful closing of its upsized initial public offering (IPO) of 9,867,000 shares of common stock. This includes the full exercise of the underwriters’ option to purchase 1,287,000 additional shares at an IPO price of $15.00 per share, with all shares being offered by Scribe Therapeutics. The company’s common stock commenced trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol “SCTX.”

The joint book-running managers for the offering included Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities. The total gross proceeds from the IPO, inclusive of the underwriters’ full option exercise and a concurrent private placement, amounted to approximately $155.51 million, prior to underwriting discounts and commissions.

A registration statement concerning the securities sold in the IPO has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on July 23, 2026. Information regarding the IPO can be accessed through the SEC's website at www.sec.gov. The offering was conducted solely via a prospectus, with final copies available from the respective underwriters.

In addition to the IPO, Scribe Therapeutics also announced the completion of a concurrent private placement of 500,000 shares of its common stock at the IPO price to Sanofi on July 27, 2026. This private placement was not registered under the Securities Act of 1933, as amended.

This press release does not constitute an offer to sell or solicit any offers to buy securities from Scribe, nor will there be any sale of these securities in jurisdictions where such an offer would be unlawful prior to registration or qualification under the applicable securities laws.

About Scribe Therapeutics Inc., the company is at the forefront of biotechnology, developing CRISPR-based technologies to create in vivo genetic medicines intended to become the standard of care for prevalent diseases, beginning with cardiometabolic conditions. Utilizing its CRISPR by Design™ methodology, Scribe is targeting critical factors in atherosclerotic cardiovascular disease (ASCVD) like elevated LDL-C and triglycerides. The lead candidate, STX-1150, aims to epigenetically silence the PCSK9 gene and lower LDL-C levels without causing permanent DNA alterations. To enhance the reach of its CRISPR technologies, Scribe has partnered with leading pharmaceutical companies, including Sanofi and Eli Lilly. Co-founded by Nobel laureate Jennifer Doudna, the company is committed to advancing scalable and transformative genetic medicines to improve health outcomes and broaden access to beneficial human genetics.

Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com

Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com